Discounted Cash Flow (DCF) Analysis Levered
Globus Medical, Inc. (GMED)
$50.77
-0.32 (-0.63%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 712.97 | 785.37 | 789.04 | 958.10 | 1,022.84 | 1,122.07 | 1,230.93 | 1,350.35 | 1,481.35 | 1,625.06 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | 181.64 | 171.97 | 198.79 | 276.27 | 178.47 | 266.72 | 292.60 | 320.98 | 352.12 | 386.28 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -59.70 | -70.75 | -63.66 | -56.90 | -74.05 | -86.69 | -95.09 | -104.32 | -114.44 | -125.54 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | 121.95 | 101.22 | 135.14 | 219.38 | 104.42 | 180.04 | 197.50 | 216.66 | 237.68 | 260.74 |
Weighted Average Cost Of Capital
| Share price | $ 50.77 |
|---|---|
| Beta | 1.076 |
| Diluted Shares Outstanding | 102.64 |
| Cost of Debt | |
| Tax Rate | 21.75 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 9.515 |
| Total Debt | - |
| Total Equity | 5,211.19 |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 712.97 | 785.37 | 789.04 | 958.10 | 1,022.84 | 1,122.07 | 1,230.93 | 1,350.35 | 1,481.35 | 1,625.06 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 181.64 | 171.97 | 198.79 | 276.27 | 178.47 | 266.72 | 292.60 | 320.98 | 352.12 | 386.28 |
| Capital Expenditure | -59.70 | -70.75 | -63.66 | -56.90 | -74.05 | -86.69 | -95.09 | -104.32 | -114.44 | -125.54 |
| Free Cash Flow | 121.95 | 101.22 | 135.14 | 219.38 | 104.42 | 180.04 | 197.50 | 216.66 | 237.68 | 260.74 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | 265.96 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -150.47 |
| Equity Value | - |
| Shares Outstanding | 102.64 |
| Equity Value Per Share | - |